Artiva Biotherapeutics, Inc. Common Stock (ARTV)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is listed on Nasdaq, where it has traded since July 19, 2024.
- Listed On
- Nasdaq
- Listed Since
- July 19, 2024
- Employees
- 115
- Market Cap
- $342M
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 69 institutions reported holding ARTV, with 40.4 million shares worth $391.6 million in aggregate. The largest reported holder was RA Capital Management,, with 18.0 million shares worth $174.2 million. Of the 5 largest holders listed below, 2 opened new positions in ARTV, 2 added shares and 1 held its position unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| RA Capital Management, | 17,955,642 | $174M | Added 82.23% |
| Viking Global Investors | 2,604,166 | $25M | New position |
| Blackstone | 2,403,437 | $23M | New position |
| 5am Venture Management | 2,353,304 | $23M | Unchanged |
| VR Adviser | 2,043,596 | $20M | Added 26.97% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is ARTV?
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is listed on Nasdaq, where it has traded since July 19, 2024.
Who are the largest institutional holders of ARTV?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of ARTV were RA Capital Management,, Viking Global Investors and Blackstone.
How many institutions own ARTV?
69 institutions reported a position in ARTV for the quarter ended June 30, 2026, worth $391.6 million in total.
Did institutions buy or sell ARTV last quarter?
Of the 5 largest reported holders, 2 opened new positions in ARTV, 2 added shares and 1 held its position unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for ARTV.
Every reported institutional holder, plus insider and congressional trades in ARTV, on SentiSense.